1 / 6

Improving the Process of Rare Disease Treatment Development

Improving the Process of Rare Disease Treatment Development. Emil D. Kakkis , M.D., Ph.D. Chief Executive Officer and President, Ultragenyx Pharmaceutical, Inc . Progress Toward Molecular Based Therapies for Neuromuscular Disease. Jerry R. Mendell , M.D.

austin
Télécharger la présentation

Improving the Process of Rare Disease Treatment Development

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Improving the Process of Rare Disease Treatment Development Emil D. Kakkis, M.D., Ph.D. Chief Executive Officer and President, Ultragenyx Pharmaceutical, Inc.

  2. Progress Toward Molecular Based Therapies for Neuromuscular Disease Jerry R. Mendell, M.D. Director, Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital

  3. Development of a 2-hydroxypropyl- β-cyclodextrin therapeutic trial for Niemann-Pick disease, type C1 Forbes D. Porter M.D., Ph.D. Senior Investigator, Program Head and Clinical Director, NICHD, NIH

  4. Development of a Novel RNAi Therapeutic, Patisiran, for the Treatment of TTRmediated Familial Amyloidotic Polyneuropathy (FAP) Akshay K. Vaishnaw, M.D., Ph.D. Executive Vice-President and Chief Medical Officer, Alnylam Pharmaceuticals, Inc.

  5. Exploration of AAV-Mediated Gene therapies for Inherited Ocular Disorders Gwyneth Jane Farrar, Ph.D. Professor of Genetics Smurfit Institute of Genetics Trinity College, Dublin

  6. Gene Therapy for Haemophilia B   UCL/St Jude's Trial Update at 4 Years Edward G.D. Tuddenham, M.D. Emeritus Professor of Haemophilia, UCL Katherine DormandyHaemophilia Centre Royal Free Hospital

More Related